The Crown and Stem of the V3 Loop Play Distinct Roles in Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Interactions with the CCR5 Coreceptor

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2002 Aug 7

PMID 12163614

Citations 128

Authors

Emmanuel G Cormier

Tatjana Dragic

Affiliations

Soon will be listed here.

Abstract

Human immunodeficiency virus type 1 envelope glycoprotein gp120 interacts with CD4 and the CCR5 coreceptor in order to mediate viral entry. A CD4-induced surface on gp120, primarily composed of residues in the V3 loop and the C4 domain, interacts with CCR5. In the present study, we generated envelope glycoproteins comprising chimeric V3 loops and/or V3 loops with deletions and studied their binding to CCR5 amino-terminal domain (Nt)-based sulfopeptides and cell surface CCR5, as well as their ability to mediate viral entry. We thus delineated two functionally distinct domains of the V3 loop, the V3 stem and the V3 crown. The V3 stem alone mediates soluble gp120 binding to the CCR5 Nt. In contrast, both the V3 stem and crown are required for soluble gp120 binding to cell surface CCR5. Within the context of a virion, however, the V3 crown alone determines coreceptor usage. Our data support a two-site gp120-CCR5 binding model wherein the V3 crown and stem interact with distinct regions of CCR5 in order to mediate viral entry.

Citing Articles

Convergent Evolution Dynamics of SARS-CoV-2 and HIV Surface Envelope Glycoproteins Driven by Host Cell Surface Receptors and Lipid Rafts: Lessons for the Future.

Fantini J, Chahinian H, Yahi N Int J Mol Sci. 2023; 24(3).

PMID: 36768244 PMC: 9915253. DOI: 10.3390/ijms24031923.

Net charge and position 22 of the V3 loop are associated with HIV-1 tropism in recently infected female sex workers in Nairobi, Kenya.

Abisi H, Otieno L, Irungu E, Onyambu F, Chepchirchir A, Anzala O Medicine (Baltimore). 2023; 101(49):e32024.

PMID: 36626483 PMC: 9750520. DOI: 10.1097/MD.0000000000032024.

Novel small synthetic HIV-1 V3 crown variants: CCR5 targeting ligands.

Anitha A, Narayanan P, Ajayakumar N, Sivakumar K, Kumar K J Biochem. 2022; 172(3):149-164.

PMID: 35708645 PMC: 9445593. DOI: 10.1093/jb/mvac052.

Discordance between HIV-1 Population in Plasma at Rebound after Structured Treatment Interruption and Archived Provirus Population in Peripheral Blood Mononuclear Cells.

Hendricks C, Cash M, Tagliamonte M, Riva A, Brander C, Llano A Microbiol Spectr. 2022; 10(4):e0135322.

PMID: 35699458 PMC: 9431602. DOI: 10.1128/spectrum.01353-22.

V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1-infected, treatment-experienced persons receiving optimized background regimens.

Lewis M, Simpson P, Mori J, Jubb B, Sullivan J, McFadyen L Antivir Chem Chemother. 2021; 29:20402066211030380.

PMID: 34343443 PMC: 8369958. DOI: 10.1177/20402066211030380.

References

Binley J, Sanders R, CLAS B, Schuelke N, Master A, Guo Y . A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol. 2000; 74(2):627-43. PMC: 111582. DOI: 10.1128/jvi.74.2.627-643.2000. View

Briggs D, Tuttle D, Sleasman J, Goodenow M . Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). AIDS. 2001; 14(18):2937-9. DOI: 10.1097/00002030-200012220-00016. View

Kwong P, Wyatt R, Sattentau Q, Sodroski J, Hendrickson W . Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol. 2000; 74(4):1961-72. PMC: 111674. DOI: 10.1128/jvi.74.4.1961-1972.2000. View

Sanders R, Schiffner L, Master A, Kajumo F, Guo Y, Dragic T . Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits. J Virol. 2000; 74(11):5091-100. PMC: 110861. DOI: 10.1128/jvi.74.11.5091-5100.2000. View

Tugarinov V, Zvi A, Levy R, Hayek Y, Matsushita S, Anglister J . NMR structure of an anti-gp120 antibody complex with a V3 peptide reveals a surface important for co-receptor binding. Structure. 2000; 8(4):385-95. DOI: 10.1016/s0969-2126(00)00119-2. View

Dragic T, Trkola A, Thompson D, Cormier E, Kajumo F, Maxwell E . A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci U S A. 2000; 97(10):5639-44. PMC: 25881. DOI: 10.1073/pnas.090576697. View

Cormier E, Persuh M, Thompson D, Lin S, Sakmar T, Olson W . Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. Proc Natl Acad Sci U S A. 2000; 97(11):5762-7. PMC: 18507. DOI: 10.1073/pnas.97.11.5762. View

Hu Q, Trent J, Tomaras G, Wang Z, Murray J, Conolly S . Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization. J Mol Biol. 2000; 302(2):359-75. DOI: 10.1006/jmbi.2000.4076. View

Farzan M, Vasilieva N, Schnitzler C, Chung S, Robinson J, Gerard N . A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry. J Biol Chem. 2000; 275(43):33516-21. DOI: 10.1074/jbc.M007228200. View

10.

Kwong P, Wyatt R, Majeed S, Robinson J, Sweet R, Sodroski J . Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure. 2001; 8(12):1329-39. DOI: 10.1016/s0969-2126(00)00547-5. View

11.

Poignard P, Saphire E, Parren P, Burton D . gp120: Biologic aspects of structural features. Annu Rev Immunol. 2001; 19:253-74. DOI: 10.1146/annurev.immunol.19.1.253. View

12.

Cormier E, Tran D, Yukhayeva L, Olson W, Dragic T . Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J Virol. 2001; 75(12):5541-9. PMC: 114266. DOI: 10.1128/JVI.75.12.5541-5549.2001. View

13.

Hatse S, Princen K, Gerlach L, Bridger G, Henson G, De Clercq E . Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. Mol Pharmacol. 2001; 60(1):164-73. DOI: 10.1124/mol.60.1.164. View

14.

Dragic T . An overview of the determinants of CCR5 and CXCR4 co-receptor function. J Gen Virol. 2001; 82(Pt 8):1807-1814. DOI: 10.1099/0022-1317-82-8-1807. View

15.

PLATT E, Kuhmann S, Rose P, Kabat D . Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region. J Virol. 2001; 75(24):12266-78. PMC: 116123. DOI: 10.1128/JVI.75.24.12266-12278.2001. View

16.

Thompson D, Cormier E, Dragic T . CCR5 and CXCR4 usage by non-clade B human immunodeficiency virus type 1 primary isolates. J Virol. 2002; 76(6):3059-64. PMC: 135972. DOI: 10.1128/jvi.76.6.3059-3064.2002. View

17.

Chesebro B, Wehrly K, Nishio J, Perryman S . Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J Virol. 1992; 66(11):6547-54. PMC: 240149. DOI: 10.1128/JVI.66.11.6547-6554.1992. View

18.

Rini J, Stanfield R, Stura E, Salinas P, Profy A, Wilson I . Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen. Proc Natl Acad Sci U S A. 1993; 90(13):6325-9. PMC: 46921. DOI: 10.1073/pnas.90.13.6325. View

19.

Catasti P, Fontenot J, Bradbury E, Gupta G . Local and global structural properties of the HIV-MN V3 loop. J Biol Chem. 1995; 270(5):2224-32. DOI: 10.1074/jbc.270.5.2224. View

20.

Dragic T, Trkola A, Lin S, Nagashima K, Kajumo F, Zhao L . Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J Virol. 1998; 72(1):279-85. PMC: 109374. DOI: 10.1128/JVI.72.1.279-285.1998. View